Previous close | 136.70 |
Open | 0.00 |
Bid | 0.00 x N/A |
Ask | 0.00 x N/A |
Day's range | 0.00 - 0.00 |
52-week range | |
Volume | |
Avg. volume | N/A |
Market cap | N/A |
Beta (5Y monthly) | 1.22 |
PE ratio (TTM) | 0.69 |
EPS (TTM) | 2.07 |
Earnings date | 05 Aug 2024 - 09 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
NEW YORK, May 30, 2024--IFF (NYSE: IFF) today announced the appointment of Margarita Paláu-Hernández to its Board of Directors, effective June 3, 2024. Paláu-Hernández joins as a mutually agreed independent Director in connection with IFF’s previously disclosed cooperation agreement with Icahn Capital LP and its affiliates. Following the appointment of Paláu-Hernández, the Board will be comprised of 11 members, ten of which are independent.
NEW YORK, May 29, 2024--IFF (NYSE:IFF) today released its 2023 Do More Good Report, describing how the Company is progressing against its environmental, social, governance, and sustainable solutions (or ESG+) strategy across the organization. The report showcases that IFF enabled customers and consumers to avoid approximately 24.6 million tonnes of CO2e emissions using IFF innovations, amongst other achievements. The new report can be experienced by visiting iff.com/domoregoodreport.
IFF (NYSE: IFF), a global leader in food and beverage, home and personal care and health will unveil groundbreaking study results at upcoming major biomedical conferences. These results highlight how IFF Pharma Solutions NovaMatrix® portfolio of ultrapure alginate biopolymers could revolutionize regenerative medicine and 3D cell culture applications. At the 12th World Biomaterials Congress (WBC), IFF Pharma Solutions will showcase a first-of-its-kind alginate hydrogel system that self-gels, offe